Select Publications
Journal articles
2024, 'Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-52194-9
,2024, 'Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans', ACS Nano, 18, pp. 27077 - 27089, http://dx.doi.org/10.1021/acsnano.4c11652
,2024, 'Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine', Journal of Clinical Investigation, 134, http://dx.doi.org/10.1172/JCI181244
,2024, 'B-cell characteristics define HCV reinfection outcome', Journal of Hepatology, 81, pp. 415 - 428, http://dx.doi.org/10.1016/j.jhep.2024.04.004
,2024, 'Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults', Science Immunology, 9, http://dx.doi.org/10.1126/sciimmunol.adj9285
,2023, 'Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis', Nature Communications, 14, pp. 1633, http://dx.doi.org/10.1038/s41467-023-37176-7
,2023, 'Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adg5301
,2023, 'SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses', Immunity, 56, pp. 879 - 892.e4, http://dx.doi.org/10.1016/j.immuni.2023.02.017
,2023, 'Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations', JCI Insight, 8, http://dx.doi.org/10.1172/jci.insight.167157
,2023, 'Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections', JCI Insight, 8, http://dx.doi.org/10.1172/jci.insight.172470
,2023, 'B Cell Signatures and Antibody Imprinting Define HCV Reinfection Outcome', , http://dx.doi.org/10.2139/ssrn.4418620
,2022, 'Early microbial exposure shapes adult immunity by altering CD8+ T cell development', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2212548119
,2022, 'The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants', Immunity, 55, pp. 1316 - 1326.e4, http://dx.doi.org/10.1016/j.immuni.2022.05.018
,2022, 'Relating in Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial', Clinical Infectious Diseases, 75, pp. E878 - E879, http://dx.doi.org/10.1093/cid/ciac075
,2022, 'Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?', Nature Reviews Immunology, 22, pp. 387 - 397, http://dx.doi.org/10.1038/s41577-022-00716-1
,2022, 'Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine', Cell, 185, pp. 1875 - 1887.e8, http://dx.doi.org/10.1016/j.cell.2022.04.009
,2022, 'Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy', Journal of Infectious Diseases, 225, pp. 1721 - 1730, http://dx.doi.org/10.1093/infdis/jiab533
,2022, 'Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory', Nature Immunology, 23, pp. 768 - 780, http://dx.doi.org/10.1038/s41590-022-01175-5
,2022, 'Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation', The Journal of Immunology, 208, pp. 125.10 - 125.10, http://dx.doi.org/10.4049/jimmunol.208.supp.125.10
,2022, 'Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis', The Lancet Microbe, 3, pp. e52 - e61, http://dx.doi.org/10.1016/S2666-5247(21)00267-6
,2021, 'mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern', Science, 374, http://dx.doi.org/10.1126/science.abm0829
,2021, 'Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-21444-5
,2021, 'Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121', Frontiers in Immunology, 12, http://dx.doi.org/10.3389/fimmu.2021.749891
,2021, 'Tracking the kinetics and phenotype of spike epitope-specific CD4 T cell immunity in the context of SARS-CoV-2 infection and vaccination', , http://dx.doi.org/10.21203/rs.3.rs-957030/v1
,2021, 'Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection', Nature Medicine, 27, pp. 1205 - 1211, http://dx.doi.org/10.1038/s41591-021-01377-8
,2021, 'Decay of Fc-dependent antibody functions after mild to moderate COVID-19', Cell Reports Medicine, 2, http://dx.doi.org/10.1016/j.xcrm.2021.100296
,2021, 'Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection', Nature Reviews Immunology, 21, pp. 395 - 404, http://dx.doi.org/10.1038/s41577-021-00550-x
,2021, 'A Dynamical Model of Dengue Primary and Secondary Infections with an Application to Microinsurance', International Journal of Mathematics and Computer Science, 16, pp. 1045 - 1062
,2021, 'Tear antibodies to SARS-CoV-2: implications for transmission', Clinical and Translational Immunology, 10, http://dx.doi.org/10.1002/cti2.1354
,2021, 'Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial', , http://dx.doi.org/10.1101/2021.06.29.21259504
,2021, 'SARS-CoV-2 variants: levels of neutralisation required for protective immunity', , http://dx.doi.org/10.1101/2021.08.11.21261876
,2021, 'Tear antibodies to SARS-CoV-2: implications for transmission', , http://dx.doi.org/10.1101/2021.08.02.21261479
,2021, 'What level of neutralising antibody protects from COVID-19?', , http://dx.doi.org/10.1101/2021.03.09.21252641
,2020, 'Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models', Nature Reviews Immunology, 20, pp. 727 - 738, http://dx.doi.org/10.1038/s41577-020-00471-1
,2020, 'Person-specific biomolecular coronas modulate nanoparticle interactions with immune cells in human blood', ACS Nano, 14, pp. 15723 - 15737, http://dx.doi.org/10.1021/acsnano.0c06679
,2020, 'Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19', Nature Medicine, 26, pp. 1428 - 1434, http://dx.doi.org/10.1038/s41591-020-0995-0
,2020, 'Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults', Vaccine, 38, pp. 2368 - 2377, http://dx.doi.org/10.1016/j.vaccine.2020.01.066
,2019, 'Interaction between maternally derived antibodies and heterogeneity in exposure combined to determine time-to-first Plasmodium falciparum infection in Kenyan infants', Malaria Journal, 18, pp. 19, http://dx.doi.org/10.1186/s12936-019-2657-6
,2019, 'Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques', Journal of Clinical Investigation, 129, pp. 182 - 191, http://dx.doi.org/10.1172/JCI122466
,2019, 'Defining early SIV replication and dissemination dynamics following vaginal transmission', Science Advances, 5, pp. eaav7116, http://dx.doi.org/10.1126/sciadv.aav7116
,2019, 'Fate mapping reveals the age structure of the peripheral T cell compartment', Proceedings of the National Academy of Sciences of the United States of America, 116, pp. 3974 - 3981, http://dx.doi.org/10.1073/pnas.1811634116
,2019, 'Cell-associated HIV RNA and the ratio of HIV RNA to DNA have circadian cycles in HIV-positive individuals on antiretoviral therapy', Journal of Virus Eradication, 5, pp. 10 - 10, http://dx.doi.org/10.1016/s2055-6640(20)31037-2
,2019, 'Fingolimod treatment at ART initiation delays SIV rebound after ART interruption', Journal of Virus Eradication, 5, pp. 3 - 3, http://dx.doi.org/10.1016/s2055-6640(20)31078-5
,2018, 'Developmental Origin Governs CD8+ T Cell Fate Decisions during Infection', Cell, 174, pp. 117 - 130.e14, http://dx.doi.org/10.1016/j.cell.2018.05.029
,2017, 'Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV', Human Vaccines and Immunotherapeutics, 13, pp. 2726 - 2737, http://dx.doi.org/10.1080/21645515.2017.1368935
,2017, 'Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption', Journal of Virology, 91, pp. 10.1128/jvi.00603 - 10.1128/jvi.00617, http://dx.doi.org/10.1128/JVI.00603-17
,2017, 'Fc functional antibodies in humans with severe H7N9 and seasonal influenza', Journal of Clinical Investigation, 2, pp. e92750, http://dx.doi.org/10.1172/jci.insight.92750
,2017, 'Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy', PLoS Pathogens, 13, pp. e1006359, http://dx.doi.org/10.1371/journal.ppat.1006359
,2017, '13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption', Journal of Virus Eradication, 3, pp. 10 - 10, http://dx.doi.org/10.1016/s2055-6640(20)30718-4
,2016, 'Modeling of EBV Infection and Antibody Responses in Kenyan Infants with Different Levels of Malaria Exposure Shows Maternal Antibody Decay is a Major Determinant of Early EBV Infection', Journal of Infectious Diseases, 214, pp. 1390 - 1398, http://dx.doi.org/10.1093/infdis/jiw396
,